copper(II) complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Tripeptide; copper binds via His and N-terminus |
| Copper stoichiometry | Typically 1 Cu(II) per peptide | Can form ternary complexes under some conditions |
| Molecular formula (peptide) | C14H24N6O4 | Free peptide; copper complex mass differs |
| Appearance (solid) | Blue to blue-green powder | Color derives from copper d-d transitions |
| Solubility | Soluble in water and polar solvents | Solubility depends on pH and counterions |
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
== Awards received while alive == In 1919, she was awarded the Notable Service Medal by President Herbert Hoover for her work in refrigeration. In 1940, she became the second recipient of the Garvan–Olin Medal, then called the Francis P. Garvan Medal, from the American Chemical Society.
Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT). It is taken orally, but can also be used by parenteral routes. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It has not been found to occur endogenously. DET is a close structural homologue of DMT and dipropyltryptamine (DPT). Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET. DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957. More systematic studies were reported later by Szára and colleagues and independently by Böszörményi and colleagues.
J. Charles Jennette is a physician, nephropathologist, academic, and author. He served as Kenneth M. Brinkhous Distinguished Professor and Chair of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine, and Chief of Pathology and Laboratory Medicine Services at UNC Hospitals from 1999 to 2019. Jennette's research focuses on understanding the causes of kidney diseases, particularly those induced by inflammatory and immunologic mechanisms, and improving the diagnosis and treatment of these diseases. He has authored and edited books, book chapters and articles in medical journals, and is an editor of four editions of the nephropathology textbook titled Heptinstall's Pathology of the Kidney. He has more than 25 named lectureships including the UNC School of Medicine 2015 Norma Berryhill Distinguished Lecture. He is the recipient of the Order of the Long Leaf Pine Award from the Governor of North Carolina for exemplary service to the State, Distinguished Service Award of the Association of Pathology Chairs, UNC Medical Alumni Distinguished Faculty Award, and Robert H. Heptinstall Lifetime Achievement Award from the Renal Pathology Society. Jennette served as the founding Secretary Treasurer of the Renal Pathology Society from 1993 until 1998, was elected vice president in 2003, and became president in 2004. He also served as President of the Association of Pathology Chairs from 2008 until 2010.
=== Pyrolysis–mass spectrometry === Pyrolysis mass spectrometry (Py-MS) is an new technique that combines pyrolysis with DART-MS or Ambient Corona Discharge Ionization-mass spectrometry for Thermal Desorption and Pyrolysis to determine the structure of small molecules and polymers.
NBOMe-LAD, also known as LSD-NBOMe, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the N-(2-methoxybenzyl) (NBOMe) derivative of LSD.
Sources: en.wikipedia.org
== External links == Nigel Scrutton's University of Manchester official website Nigel Scrutton's research group website SYNBIOCHEM website Future Biomanufacturing Research Hub website C3 Biotechnologies Ltd official website
It had two taxiways and a 6,800-by-400-foot (2,070 by 120 m) runway. In June 1945, the 67th CB arrived to build a 35,000 man recreation center to be turned over to CBMU 608. In 1950, John C. Woods, who executed the Nazi war criminals convicted at the Nuremberg trials, died by accidental electrocution while stationed on Enewetak Atoll.
=== Mechanism === ERAP1 uses a catalytic mechanism similar to the one proposed for LTA4 hydrolase. ERAP1 adopts a thermolysinlike fold and has been crystallized in two distinct conformations: a. the open and b. the closed (Figure 2). In the open conformation, domain IV lies away from the active site thus making the internal cavity more accessible to substrates. In the closed conformation, the internal cavity is occluded from the external solvent, and it is of adequate size to accommodate a 16-residue peptide. The catalytic residues and in particular Tyr438 are optimally positioned for catalysis in the closed conformation. Consequently, substrate binding is hypothesized to take place in the open conformation, while N-terminal bond cleavage takes place in the closed one. It has been proposed that binding of substrate or small inhibitors induces conformational closing of ERAP1 in solution. ERAP1 prefers peptide substrates 9-16 amino acids long and is much less active for peptides 8-9 amino acids long. It is considered that ERAP1 uses a "molecular ruler" mechanism, according to which the substrate binds through its hydrophobic C-terminus in a hydrophobic pocket at the junction of domain III and domain IV and the N-terminus binds to the active site. When the length of the peptide is shorter than 8 or 9 amino acids, the peptide is too short to reach the active site, limiting rates of cleavage. ERAP1 has a wide substrate specificity with a preference for hydrophobic residues (e.g. leucine and methionine) at the N-terminus of the peptide substrate.
== Reactions == DBNPA decomposition is dominated by two reaction pathways: pH-dependent hydrolysis and light-catalyzed reactions with reducing nucleophiles. DBNPA's electrophilic bromine atoms and electron-withdrawing cyano (-CN) group play a major role in determining its reactivity. A number of variables, including temperature, pH, light exposure, and reducing agents, have a substantial impact on the rate and mechanism of DBNPA breakdown. Different organic and inorganic byproducts could therefore develop, which could have an impact on DBNPA's toxicity and biocidal effectiveness.
Sources: en.wikipedia.org
== Academic achievements and research == Holick is an author of more than 400 publications about the biochemistry, physiology, metabolism and photobiology of vitamin D and the pathophysiology of vitamin D deficiency. He has been quoted and his scientific work has been referenced in The New York Times, Forbes, Newsweek, Men's Health, Scientific American and Time. He wrote several books about the importance of vitamin D and its beneficial health effects to the broad public, and discussed the benefits of sensible and the risks of excessive sun exposure. As a graduate student, he identified the major circulating form of vitamin D, 25-hydroxyvitamin D3, which is the vitamin D metabolite that is measured by physicians worldwide to determine a patient's vitamin D status. He also identified the active form of vitamin D, 1,25-dihydroxyvitamin D3, as well as other metabolites including 24,25-dihydroxyvitamin D3, 1,24,25-trihydroxyvitamin D3 and 25,26-dihydroxyvitamin D3. As a fellow, he participated in the first chemical synthesis of 1,25-dihydroxyvitamin D3 and 1α-hydroxyvitamin D3 to treat renal osteodystrophy, hypoparathyroidism, vitamin D dependent rickets type I, and osteoporosis. Furthermore, he elucidated the pathophysiology of hereditary vitamin D-dependent rickets which involves defective vitamin D metabolism, and the pathophysiological mechanisms of X-linked hypophosphatemic rickets.
== Awards and honors == National Outstanding Researcher Award (2019) First Prize in Applied Research Projects, 33rd Khwarizmi International Award (2019) Iran Book of the Year Award (2020), for "Peptide Chemistry in Persian" Distinguished University Professor in Iran, Ministry of Science, Research and Technology (2021) Distinguished Organic Chemistry Professor in Iran, by Iranian Chemical Society (2013) Alexander von Humboldt Foundation Research Fellowship: Awarded multiple research stays (2002, 2004, 2007, 2011, 2014, 2017) Scientific Ambassador of the Alexander von Humboldt Foundation in Iran (2015–2020) Outstanding Researcher Award, K.N. Toosi University of Technology (multiple years)
== Treatment == Treatment of established disease may include medications to lower cholesterol, such as statins, blood pressure medication, or medications that decrease clotting, such as aspirin. Many procedures may also be carried out such as percutaneous coronary intervention, coronary artery bypass graft, or carotid endarterectomy. Medical treatments often focus on alleviating symptoms. However, measures that focus on reducing underlying atherosclerosis, rather than simply treating symptoms, are more effective. Non-pharmaceutical means are usually the first method of treatment, such as stopping smoking and practicing regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases and, with improvements, have increasingly become the most effective method over the long term. The key to more effective approaches is to combine different treatment strategies. In addition, for those approaches, such as lipoprotein transport behaviors, which have been shown to produce the most success, adopting more aggressive combination treatment strategies taken daily and indefinitely has generally produced better results, both before and especially after people are symptomatic.
The first step is the condensation of three amino acids—L-α-aminoadipic acid, L-cysteine, L-valine into a tripeptide. Before condensing into the tripeptide, the amino acid L-valine must undergo epimerization to become D-valine. The condensed tripeptide is named δ-(L-α-aminoadipyl)-L-cysteine-D-valine (ACV). The condensation reaction and epimerisation are both catalysed by the enzyme δ-(L-α-aminoadipyl)-L-cysteine-D-valine synthetase (ACVS), a nonribosomal peptide synthetase or NRPS. The second step in the biosynthesis of penicillin G is the oxidative conversion of linear ACV into the bicyclic intermediate isopenicillin N by isopenicillin N synthase (IPNS), which is encoded by the gene pcbC. Isopenicillin N is a very weak intermediate, because it does not show strong antibiotic activity. The final step is a transamidation by isopenicillin N N-acyltransferase, in which the α-aminoadipyl side-chain of isopenicillin N is removed and exchanged for a phenylacetyl side-chain. This reaction is encoded by the gene penDE, which is unique in the process of obtaining penicillins.
==== Adverse effects on public health ==== Public health and policy researchers at Yale University and the University of Pennsylvania sent a letter to Senate leaders warning that cuts to health programs in the bill would lead to over 51,000 preventable deaths annually.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low and vary with physiological state. Its natural functions are not fully established.
Copper binding changes the peptide's charge, shape, and reactivity. The complex can participate in redox chemistry and interact with proteins differently than the free peptide. These differences are why studies specify whether they used GHK or GHK-Cu.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.